Biotech News

Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference

Adagene (ADAG)Adagene2026-10-14 12:00 ESTConference / presentation

Adagene Inc. (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene’s Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will participate in a fireside chat at the H.C. Wainwright 4 th Annual Immune Cell Engager Virtual Conference being held virtually on October 15, 2026.

Related news

ADAGAdagene2026-10-27 11:00 EST

Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference

GERNGeron2026-11-03 13:00 EST

Geron Corporation to Participate in the Stifel 2026 Healthcare Conference

COGTCogent Biosciences2026-10-27 20:01 EST

Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference

CHRSCoherus BioSciences, Inc.2026-10-27 13:30 EST

Coherus to Participate in Upcoming Investor Conferences

PRLDPrelude Therapeutics2026-10-16 20:01 EST

Prelude Therapeutics to Participate in the Chardan Healthcare Conference

MMSIMerit Medical2026-11-05 14:25 EST

Merit Medical Presents Real-World Data from the AVF Cohort of the WRAP Global Registry

SNDXSyndax Pharmaceuticals2026-11-04 14:01 EST

Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026

EXELExelixis2026-11-03 21:05 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November

URGNUroGen Pharma2026-11-03 13:00 EST

UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference

ZNTLZentalis2026-10-18 22:05 EST

Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract

View all latest news

Adagene

Adagene is a biotechnology company focused on next-generation antibody engineering and cancer immunotherapy. Its story is built around precision antibody design and the effort to create differentiated oncology medicines.

Recent company news

ADAGAdagene2026-10-28 11:00 EST

Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte’s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer

ADAGAdagene2026-10-27 11:00 EST

Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference

ADAGAdagene2026-10-14 12:00 EST

Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference

ADAGAdagene2026-09-22 12:00 EST

Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager

ADAGAdagene2026-09-10 12:00 EST

Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology

Stock data

Close: 2.02 USD
Market cap: 223.99M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States